Clinical trials: Urinary Frequency More Than Once at Night
Obstructive Sleep Apnea, Nocturia
Mandibular Advancement Device and Changes in Nocturia
The main purpose of this study is to test is mandibular advancement device (MAD) use is associated with reductions in nocturia.
- Conditions
- Obstructive Sleep Apnea, Nocturia, OSA
- Trial name
- MAD (NCT05562388)
- Testing
- Somnodent Classic
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Isabel Moreno Hay
Sleep Fragmentation, Poor Quality Sleep
Impact of Behavioral Treatment of Insomnia on Nighttime Urine Production
Nocturia is prevalent in older adults and it vastly reduces quality of life. Yet its treatment remains inadequate because its causes are not well understood, especially nocturnal polyuria or increased urine production at night.
- Conditions
- Sleep Fragmentation, Poor Quality Sleep, Nocturia, Nocturnal Enuresis
- Trial name
- NCT03883724
- Testing
- Brief behavioral treatment of insomnia (BBTI), Information-only control (IC)
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Nocturia, Hypertension
Sleep, Hypertension, and Nocturia: a Multicomponent Approach for Comorbid Illnesses
In this study the investigators target three common and comorbid illnesses among older adults namely nocturia or waking at night to void, poor sleep and hypertension.
- Conditions
- Nocturia, Hypertension, Sleep Disturbance
- Trial name
- SHyN (NCT05419830)
- Testing
- BBTI, PM antihypertensive dosing or Chronotherapy, AM antihypertensive dosing
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Nocturia, Prostatic Hyperplasia
A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH
- Trial name
- NCT00793819
- Testing
- silodosin
- Where
- 27 sites in United States
- Volunteers
- 215 people
- Sponsor
- Watson Pharmaceuticals
Overactive Bladder, Urinary Incontinence
The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
This study aims to assess the efficacy of a specialized herbal formula, Urox, versus control over 8 weeks, in a double blind, placebo controlled trial.
- Conditions
- Overactive Bladder, Urinary Incontinence, Urinary Frequency or Urgency Adverse Event, Nocturia
- Trial name
- NCT02396160
- Testing
- Urox
- Volunteers
- 150 people
- Sponsor
- The University of Queensland
Nocturia
Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial
This is a multi-center, double-blind, placebo-controlled study with two weeks of daily oral administration of one of three dose levels of Paxerol or placebo in subjects with nocturia.
- Trial name
- NCT02646826
- Testing
- Paxerol - Dose Level 1, Paxerol - Dose Level 2, Paxerol - Dose Level 3
- Where
- 4 sites in United States
- Volunteers
- 86 people
- Sponsor
- Wellesley Pharmaceuticals, LLC
Flank Pain, Urinary Bladder, Overactive
Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms
Most ureteral stent insertions follow ureteroscopy procedures for stone management. Stents are essentially designed to prevent the blockage of the ureter.
- Trial name
- NCT01381120
- Testing
- Solifenacin succinate treatment, Oxycodone and acetaminophen combination treatment
- Where
- Canada
- Volunteers
- 84 people
- Sponsor
- Barrie Urology Associates
Nocturia
Long Term Safety Assessment of SER120 in Patients With Nocturia
The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.
- Trial name
- NCT00981682
- Testing
- SER120
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- Serenity Pharmaceuticals, Inc.
Nocturia
Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients
The purpose of this trial was to confirm/establish long-term safety and efficacy of desmopressin orally disintegrating tablets at dose levels of 50 μg and 75 μg and to further evaluate the safety of an efficacious higher dose…
- Trial name
- NCT01262456
- Testing
- Desmopressin
- Where
- 56 sites in United States, Canada
- Volunteers
- 395 people
- Sponsor
- Ferring Pharmaceuticals
Overactive Bladder, Parkinson Disease
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
The impact of urinary symptoms in Parkinson disease (PD) extends beyond worsened well-being. Urinary symptoms common in PD, especially incontinence and nocturia, are major risk factors for falls likely due to the combination of…
- Trial name
- BOSS PD (NCT03149809)
- Testing
- solifenacin, Pelvic floor muscle exercise-based behavioral therapy
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- VA Office of Research and Development
BPH, Prostate Hyperplasia
MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)
Over 100,000 BPH procedures are performed annually in the US. The purpose of this study is to evaluate the effectiveness of performing MRI guided transrectal laser ablation using a 980 nm laser (VisualaseTM by Medtronic, Inc., a…
- Conditions
- BPH, Prostate Hyperplasia, Urinary Frequency/Urgency
- Trial name
- NCT03131544
- Testing
- MRI Guided Transrectal Periuretheral Transitional Zone Ablation
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Prostate Laser Center, PLLC
Nocturia
Treatment of Patients With Nocturia (Non-PK Study)
The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.
- Trial name
- NCT00937378
- Testing
- SER120
- Where
- United States
- Volunteers
- 326 people
- Sponsor
- Serenity Pharmaceuticals, Inc.
Nocturia
Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia
The purpose of this study is to investigate the efficacy and safety of several doses of the melt formulation of desmopressin in a broad population of adult patients with nocturia.
- Trial name
- NCT00477490
- Testing
- desmopressin acetate
- Where
- 80 sites in United States, Canada
- Volunteers
- 799 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia
Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo
This is a multi-centre, randomised, placebo-controlled, double-blind, parallel-group comparative trial to be conducted in nocturia patients.
- Trial name
- NOC (NCT01184859)
- Testing
- Desmopressin
- Where
- 36 sites in Japan
- Volunteers
- 116 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia
Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
The purpose of this study is to assess psychometric properties (reliability and validity) of the Nocturia Impact (NI) diary. To assess the association between reduction of number of nocturnal voids and the mean changes in NI…
- Trial name
- IMPACT (NCT01552343)
- Testing
- Desmopressin
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia
Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients
A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the safety and efficacy of desmopressin oral melt tablets against placebo during 3 months of treatment in adult females with…
- Trial name
- COMFORT (NCT01223937)
- Testing
- Desmopressin
- Where
- 45 sites in United States, Canada
- Volunteers
- 268 people
- Sponsor
- Ferring Pharmaceuticals
Overactive Bladder
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
This study is designed to assess the efficacy of a flexible dose regimen of fesoterodine on micturition related nocturnal urgency episodes.
- Trial name
- NCT00911937
- Testing
- Fesoterodine
- Where
- 112 sites in United States
- Volunteers
- 963 people
- Sponsor
- Pfizer
Nocturia Associated With Nocturnal Polyuria
Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)
Documentation of the efficacy and safety of desmopressin (Nocturin®) 0.1 mg tablet. Observation of patients with benign prostate syndrome, in whom nocturia associated with nocturnal polyuria is treated with desmopressin…
- Trial name
- NCT00902265
- Testing
- desmopressin
- Where
- 140 sites in Germany
- Volunteers
- 138 people
- Sponsor
- Ferring Pharmaceuticals
Overactive Bladder, Incontinence
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
This purpose of this study is to understand the types of bacteria that are in the bladder and vagina in patients with overactive bladder (OAB) symptoms and understand if the types of bacteria change when with the use of estrogen…
- Conditions
- Overactive Bladder, Incontinence, Nocturia
- Trial name
- FUM (NCT02835846)
- Testing
- Estrogen Cream
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Loyola University
Urinary Incontinence
A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
This study is being done to compare frequency of urination during the night when women take tolterodine tablets vs. when they take placebo tablets.
- Trial name
- NCT00323635
- Testing
- tolterodine
- Where
- 2 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital